From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
|Videos|October 22, 2021
What To Know About Multiple Sclerosis as a Pharmacist
Pharmacy Times spoke with neurologist Dr. Tirisham Gyang and pharmacist Dr. Margaret Hansen about multiple sclerosis, including diagnosis, treatment options, and the role of the pharmacist in patient care.
Advertisement
Pharmacy Times spoke with neurologist Dr. Tirisham Gyang and pharmacist Dr. Margaret Hansen about multiple sclerosis, including diagnosis, treatment options, and the role of the pharmacist in patient care.
Advertisement
Related to this article
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
2
Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data
3
Cystatin C and the Future of Kidney Function Assessment
4
Ribociclib Survival Data Anchor a Sobering ESMO 2026 for Breast Cancer
5